Navicon has completed a project for Microgen, the largest Russian manufacturer of immunobiological products, aimed to automate the analysis of secondary sales data. Navicon TDC (previously SalesOut) solution based on Microsoft SQL Server coordinates the distribution of 350 Microgen's products manufactured by the company's nine sites all over the country. Microgen is renting Navicon's software, which decreases the infrastructure cost and allows Microgen to reallocate resources to the renovation of its own facilities.
Microgen’s top management wanted a clear vision on how and through which channels the company’s products are selling, what medications are in high demand and what are overstocked. Manual processing of the data received from distributors used to cause frequent errors such as data doubling due to technical or human factors. Therefore, it was difficult to understand the real business situation. Then the company decided to automate the collection and analysis of secondary sales data by implementing Navicon Pharma Trade Data Consolidation (TDC).
To sum up, the pharmaceutical manufacturer got a convenient tool to analyze its sales via distributors and to detect market trends: the data from the partners' local ERPs is being quickly aggregated in a centralized storage and is readily available for analysis by geographical areas, sales channels, medication groups, dosage forms, etc. Thanks to a preset automated checkup, information doubling is also ruled out because the system transforms the data into a unified format with unified spelling for addresses, titles, and selling points.
Microgen's development strategy is to meet the Russian market's demand for high-quality Russian immunobiological remedies and to renovate its assets by 2020. The company is going to renovate its means of production using only its own revenue, without state financial support.
Microgen is one of the leading companies in the Russian pharmaceutical industry and a part of Rostec state corporation. Microgen was established in 2003 when several state pharmaceutical companies merged their forces in order to start competitive biotechnological production in Russia. Currently Microgen does scientific research in immunobiology and produces remedies, of which more than 120 are immunobiological, while more than 60 are of vital importance. The company’s revenue in 2016 was about 7,6 billion RUR.